If you have been reading about 合成肽 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
== Biological activity == Amines are ubiquitous in biology. The breakdown of amino acids releases amines, famously in the case of decaying fish which smell of trimethylamine. Many neurotransmitters are amines, including epinephrine, norepinephrine, dopamine, serotonin, and histamine. Protonated amino groups (–NH+3) are the most common positively charged moieties in proteins, specifically in the amino acid lysine. The anionic polymer DNA is typically bound to various amine-rich proteins. Additionally, the terminal charged primary ammonium on lysine forms salt bridges with carboxylate groups of other amino acids in polypeptides, which is one of the primary influences on the three-dimensional structures of proteins.
South Africa The model remained in production in South Africa, as an entry-level model until 2003. It was also sold there as the "Midge", the "Sting", and as the "Ford Tonic". A locally designed pickup based on the Familia front end, called the Rustler was also produced, and sold as the "Ford Bantam". From 1991 to 1994 Samcor also produced and sold the 323 with the 2.0 L 16-valve DOHC FE engine from the Mazda 626 and badged it "200i". Along with the 2.0 L 16-valve DOHC engine there were upgrades to the suspension and braking system. Still, the 1.6-litre GT-Ae homologation car was more powerful. This South African built model was also sold in Australia between 1989 and 1991 with minor changes, the most noticeable one being the front indicators having a clear color rather than the normal amber. These models were labeled BF as opposed to the next generation's BG.
== Treatment == Currently this sub-type of muscular dystrophy has no cure and no definitive treatment exists. Treatment offers preventative tactics to delay muscle breakdown and increase life expectancy. Stretching and physical therapy can increase mobility. Treatment also includes correcting skeletal abnormalities through orthopedic surgery and other orthopedic techniques. Antiepileptic medication is administered to help prevent seizures. ACE inhibitors and beta blockers help treat heart conditions, and respiratory assistance is more than likely needed at some point for the affected individual.
=== Crucibles === DSC measurements without crucibles promote the thermal transfer towards the sample and are possible if the DSC is designed for this purpose. Measurements without crucible should only be conducted with chemically stable materials at low temperatures, as otherwise there may be contamination or damage of the calorimeter. The safer way is to use a crucible, which is specified for the desired temperatures and does not react with the sample material (e.g. alumina, gold or platinum crucibles). If the sample is likely to evolve volatiles or is in the liquid state, the crucible should be sealed to prevent contamination. However, if the crucible is sealed, increasing pressure and possible measurement artefacts due to deformation of the crucible must be considered. In this case, crucibles with very small holes (∅~50 μm) or crucibles that can withstand very high pressures should be used.
In November 1953, Florey was informed that works would proceed as planned. On 27 March 1958, Florey ceremoniously opened the John Curtin School of Medical Research and received an honorary Doctor of Science degree along with Sir Norman Gregg. Menzies, Coombes, Ennor and Curtin's family were in attendance. This was not the end of Florey's association with the ANU. In 1964, he accepted the role of chancellor, a position he held from 1965 until his death in 1968.
Sources: en.wikipedia.org
Weak affinity chromatography (WAC) is an affinity chromatography technique for affinity screening in drug development. WAC is an affinity-based liquid chromatographic technique that separates chemical compounds based on their different weak affinities to an immobilized target. The higher affinity a compound has towards the target, the longer it remains in the separation unit, and this will be expressed as a longer retention time. The affinity measure and ranking of affinity can be achieved by processing the obtained retention times of analyzed compounds. Affinity chromatography is part of a larger suite of techniques used in chemoproteomics based drug target identification. The WAC technology is demonstrated against a number of different protein targets – proteases, kinases, chaperones and protein–protein interaction (PPI) targets. WAC has been shown to be more effective than established methods for fragment based screening. Affinity chromatography was conceived and first developed by Pedro Cuatrecasas and Meir Wilchek.
2 NpO2 + H2 + 6 HF → 2 NpF3 + 4 H2O (400°C) 2 NpF3 + O2 + 2 HF → 2 NpF4 + H2O (400°C) Later, NpF4 was obtained directly by heating NpO2 to various temperatures in mixtures of either hydrogen fluoride or pure fluorine gas. NpF5 is much more difficult to form and most known preparation methods involve reacting NpF4 or NpF6 compounds with various other fluoride compounds. NpF5 will decompose into NpF4 and NpF6 when heated to around 320 °C. NpF6 or neptunium hexafluoride is extremely volatile, as are its adjacent actinide compounds uranium hexafluoride (UF6) and plutonium hexafluoride (PuF6). This volatility has attracted a large amount of interest to the compound in an attempt to devise a simple method for extracting neptunium from spent nuclear power station fuel rods. NpF6 was first prepared in 1943 by reacting NpF3 and gaseous fluorine at very high temperatures and the first bulk quantities were obtained in 1958 by heating NpF4 and dripping pure fluorine on it in a specially prepared apparatus. Additional methods that have successfully produced neptunium hexafluoride include reacting BrF3 and BrF5 with NpF4 and by reacting several different neptunium oxide and fluoride compounds with anhydrous hydrogen fluorides. Four neptunium oxyfluoride compounds, NpO2F, NpOF3, NpO2F2, and NpOF4, have been reported, although none of them have been extensively studied. NpO2F2 is a pinkish solid and can be prepared by reacting NpO3·H2O and Np2F5 with pure fluorine at around 330 °C.
Dalton's law – Empirical law of partial pressures Charles's law – Relationship between volume and temperature of a gas at constant pressure Ideal gas law – Equation of the state of a hypothetical ideal gas
==== Differential ==== A differential backup saves only the data that has changed since the last full backup. This means a maximum of two backups from the repository are used to restore the data. However, as time from the last full backup (and thus the accumulated changes in data) increases, so does the time to perform the differential backup. Restoring an entire system requires starting from the most recent full backup and then applying just the last differential backup. A differential backup copies files that have been created or changed since the last full backup, regardless of whether any other differential backups have been made since, whereas an incremental backup copies files that have been created or changed since the most recent backup of any type (full or incremental). Changes in files may be detected through a more recent date/time of last modification file attribute, and/or changes in file size. Other variations of incremental backup include multi-level incrementals and block-level incrementals that compare parts of files instead of just entire files.
Sources: en.wikipedia.org
== Adorno's sociological methods == Adorno believed that the language the sociologist uses, like the language of the ordinary person, is a political construct in large measure that uses, often unreflectingly, concepts installed by dominant classes and social structures. He felt that "those at the top of the Institute needed to be the source primarily of theories for evaluation and... empirical testing, as well as people who would process the "facts" discovered... including revising theories that were found to be false." For example, in an essay published in Germany on Adorno's return from the US, and reprinted in the Critical Models essays collection, Adorno praised the egalitarianism and openness of US society based on his sojourn in New York and the Los Angeles area between 1935 and 1955: "Characteristic for the life in America [...] is a moment of peacefulness, kindness and generosity." One example of the clash of intellectual culture and Adorno's methods can be found in Paul Lazarsfeld, the American sociologist for whom Adorno worked in the late 1930s after fleeing Hitler. As Rolf Wiggershaus recounts in The Frankfurt School, Its History, Theories and Political Significance (MIT 1995), Lazarsfeld was the director of a project, funded and inspired by David Sarnoff (the head of RCA), to discover both the sort of music that listeners of radio liked and ways to improve their "taste" so that RCA could profitably air more classical music.
Lysyl oxidase the terminal carbon of the side chain of lysyl residue side chain. The enzyme belongsthe category of quinone-containing copper amine oxidases. The reaction requires the cofactor lysyl tyrosylquinone (LTQ). The LTQ cofactor is unique among quinones because it contains an 1,2-benzoquinone substituent. Furthermore, it is neutral charge at physiological pH. The ε-amine is condenses with LTQ to give the Schiff base via reaction with LTQ. The rate-limiting removal of a ε-proton yields an imine. Subsequent hydrolysis of the imine leads to release of the allysine residue. Molecular oxygen and the copper ion are utilized to reoxidize the cofactor, producing hydrogen peroxide as a side product.
Frankincense has been traded on the Somali and Arabian Peninsula for centuries. Greek historian Herodotus wrote in The History that frankincense was harvested from trees in southern Arabia. Pliny the Elder mentioned frankincense in the Naturalis Historia. Frankincense, which was used in the Roman Empire prior to the spread of Christianity, was reintroduced to Western Europe possibly by Frankish Crusaders and other Western Europeans on their journeys to the Eastern Roman Empire, where it was commonly used in Catholic Mass. Southern Arabia was an exporter of frankincense in antiquity, with some of it being traded as far as China. The 13th-century Chinese writer and customs inspector Zhao Rugua wrote that Ruxiang or xunluxiang (Chinese: 乳香 rǔ xiāng/ 薰陸香 xūn lù xiāng) comes from the three Dashi states (Chinese: 大食 dàshí – Caliphate (Arab Muslims)) of Maloba (Murbat), Shihe (Shihr), and Nufa (Dhofar), from remote mountains; the trunk of the tree is notched with a hatchet, upon which the resin flows out, and, when hardened, turns into incense, which is gathered and made into lumps; it is transported to the Dashi ports, then on ship to Sanfoqi.
The amyloid formation might be a major mediator of apoptosis, or programmed cell death, in the islet β-cells. Initially, the proIAPP aggregates within secretory vesicles inside the cell. The proIAPP acts as a seed, collecting matured IAPP within the vesicles, forming intracellular amyloid. When the vesicles are released, the amyloid grows as it collects even more IAPP outside the cell. The overall effect is an apoptosis cascade initiated by the influx of ions into the β-cells.
== Overdose == In the event of an overdose of oral ketoconazole, treatment should be supportive and based on symptoms. Activated charcoal may be administered within the first hour following overdose of oral ketoconazole.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.